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ABSTRACT

Introduction
Collection, processing and distribution of safe blood in Tanzania occurs within a
free-for-service context, that is, a collection from non-remunerated blood
donors and distributing freely to the needy people through health facilities.
The safe blood services in the country appear to be crippled with many
challenges and cannot meet the demand for blood and its products. As such, a
need for rethinking collection methods, financial models and possible
mechanisms for donor remuneration is evident.
Methods
In this paper, we venture on multi-stakeholder meetings and ongoing
discussions regarding the internal mechanisms of safe blood transfusion
financing. The intent is to offer a perspective on the considerations for selfsustaining safe blood services in the country and the extent to which they may
be implemented or not.
Results
We suggest that despite huge demand, the external donor dependent
financing mechanisms for safe blood services in the country are ineffective.
Therefore, we discuss two potential ‘internal’ financing mechanisms that have
been identified in recent shareholders forums 1) introducing a blood processing
fee accompanied by policy change to allow direct charging of either recipients
or hospitals or 2) influencing the introduction of ‘blood services’ within the
current insurance schemes.
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Conclusion
We conclude that there is a need for constructing alternative financial mechanisms to sustain the demand of
safe blood in the country. We discuss two cost recovery mechanisms, blood processing fee and insurance
schemes; however, warning is noted that their implementation warrants structural adjustments, massive
community sensitization and optimum stakeholder engagement to maximize acceptability within the
country.
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INTRODUCTION

Safe blood supply is an important facet of health care
services in any country. The benefits of safe blood
services extend beyond saving lives of millions of
mothers and others in need of blood products to the
reduction in transfusion-transmissible infections such
as HIV, Hepatitis B and C Viruses and syphilis among
blood recipients.1 – 6 For example, between 2004 and
2012, safe blood services was considered to
contribute in reducing prevalence of transfusion
related HIV from 7-percent to 1-percent, syphilis and
Hepatitis C stands at less than 1-percent in Tanzania.6
It is for these reasons that a need for sustainable
blood supply is indispensable.
Safe blood supply in Tanzania envisages three steps
which are; collection of blood from voluntary nonenumerated donors, processing and distribution to
hospitals who then transfuse all patients in need.6 - 8
The National Blood Transfusion Services (NBTS), an
entity which deals with regulating, collection,
processing and distribution of safe blood in the
country 7 has continued to embrace donor and public
funding of services “to ensure easily accessible and
adequate supply of safe and high quality blood….to
all who need it irrespective of their economic or
social status.” The entity, therefore handles the
training of staff, blood collection, storage and
transportation activities within the country.
Furthermore, the agency is expected to provide
guidance to all actors for the betterment of blood
transfusion practices and ensure harmony and the
use of standardized guidelines across institutions.7
While the agency has continued to achieve its
administrative roles; challenges in financing safe
blood in the country persist.
There is unmatched funding in comparison to the
persistently increasing demand for safe blood in the
country. NBTS reports indicate that donor funds
decreased from 72-percent of total funds in 2006 to
49-percent in 2011.6,9 Interestingly, the annual
demand for blood in 2013 was estimated to exceed
450,000 units per year, which required $10,752,000,
with NBTS only able to meet 30-percent of the
need.6, 8, 9 This unfavorable trend has sparked off a
discussion among stakeholders for diversifying
financial resources. The decrease in ‘external’ funds
2
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has propelled the stakeholders to eye on financial
mechanisms from the ‘internal’ sources. As such,
there have been efforts to advocate for diversified
cost recovery mechanisms, particularly from the
direct beneficiaries of blood transfusion.8 In this
article, we present the potential internal sources that
have been a hallmark of stakeholder discussions and
key issues to consider in their implementation within
the country.
METHODS

This paper is descriptive in nature, venturing on the
proceedings of the multi-stakeholders’ task force in
Tanzania between 2014 and 2015 and the ongoing
discussions afterwards. The goal of this task force
was to review the current blood financing
mechanisms in Tanzania and to guide the agency in
discerning a way forward. The group, comprising of
NBTS staffs, stakeholders and experts met three
times within a year and brainstormed about potential
internal financial mechanisms for blood services.
Since then, the discussion on the topic is ongoing.
RESULTS

The group acknowledged that there is a huge
demand for blood products within the country,
however, the external donor dependent financing
mechanisms for safe blood services are inadequate
and unsustainable. The NBTS was established
through an agreement between donor government
and the Tanzania Government in 2004 in line with the
World Health Assembly Resolution WHA 28.72
(1972); which urges all member states to develop
comprehensive
and
well-coordinated
blood
transfusion services based on voluntary, nonremunerated blood donors.7 Since its establishment,
the agency has mainly depended on external donors
which has been greatly inconsistent with donors
‘tapering’ their funds (Table 1). As such, there is a
need to consider internal sources for financing safe
blood transfusion services to ensure sustainability.
The decreased funding means that Tanzania is
unable to meet the blood transfusion services cost.
For example, the NBTS suggests that the operating
cost of suitable and safe blood in the country is about
$ 76.8 per unit in Tanzania entailing the cost incurred
in the recruitment, collection, screening, testing,
production, distribution and health education.9
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However, the estimated annual demand for safe
blood appears to exceed the agency supply

Year

Amount
required
(USD)

2006
2009
2010
2011

5,500,000
6,200,000
6,300,000
6,400,000

Table 1 Financing Trend for NBTS, 2006 – 2011
Amount received
Amount received from
Total amount
from MOHSW
CDC and other donors
received (USD)
(USD)
(USD)
0
270,000(4%)
560,000(9%)
177,000(3%)

Source: National Blood Transfusion Services

3,945,885(72%)
3,900,000(63%)
4,000,000(64%)
3,150,000(49%)

Given the insufficiency of external financial donations
(Table 1), the huge financial requirements for
collection, processing and distribution; and
inadequate cost recovery mechanisms, the country
lacks the capacity to meet the demand. Therefore,
the group unmasked two potential ‘internal’ blood
financing mechanisms. Firstly, the introduction of
blood processing fee and subsequent policy changes
and influencing the introduction of ‘blood services’
within the current insurance schemes.
The introduction of blood processing fee as a way of
cost recovery through direct charging blood
recipients in terms of user fees or hospitals is
consistent with Gerald and colleagues10 who suggest
that cost recovery mechanisms can be done by
1.Spreading the cost of blood across user fees paid
by all inpatients
2. Charging the recipient of blood directly and
3. Charging hospitals directly for blood used.
While we propose the introduction of blood
processing fee in the country, we understand that
this approach is not without its challenges. To start
with, the NBTS’s focus and mission may need to
undergo some changes. The agency’s mission
categorizes blood and its products as ‘a public good’
because it is collected from voluntary, nonremunerated blood donors.6,9 Voluntary, nonremunerated donation is promoted by the World
Health Organization.1, 11 Boyle and colleagues 12 also
concur with WHO as their report indicates lower risk
www.gjmedph.com Vol. 5, No. 4 2016

3,954,885(72%)
4,170,000(67%)
4,560,000(72%)
3,327,000(52%)

Variance
(USD)
1,554,115(28%)
2,030,000(33%)
1,740,000(28%)
3,073,000(48%)

6,9

DISCUSSION

3

capacity.6,8,9

of HIV transmission in volunteer donors than paid or
family donors. Since blood is obtained ‘free’ making
it a public good, charging for it will necessitate
changing the agency’s mission and their strategic
approaches.
Additionally, there are ethical concerns to consider
regarding safe blood services and the charging of
patients. Ethically, charging an individual patient
may not be justifiable due to the fact that blood is
not only freely donated but is also transfused to
clinically ill patients, carefully selected and those in
need for it.13 Furthermore, most of the blood
recipients are mainly under-five children and
pregnant women who are exempted under the
current health service structure.6, 8, 9, 14 Embracing
the fee exemption to this group will inevitably
reduce the possible revenue base significantly. As
such, policy change or charging the hospital may be
a necessity. Lastly, is the practicability of introducing
user fees in the country at a time when the political
environment is fragile. We revisited the experiences
of Malawi and other countries and noted that in
many countries, only a limited portion of the cost of
providing safe blood can realistically be raised from
users. Therefore, cost recovery from user fees even
in policy change, maybe challenging to implement in
the country.
We therefore suggest that, if NBTS were to conceive
the user fee as an option, any attempt to implement
the proposed strategies in the country would require
the following
1.Large-scale policy change to create friendly
ISSN#- 2277-9604
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political and social environment for charging for
blood,
2.Seeking approval from the ‘public’ who are
‘volunteers’ and ‘not remunerated’ for the ‘products’
they donate
3.Intra-country advocacy for treating blood as an
essential product.
After a long debate and global advocacy2,3 the recent
WHO essential medicine list appears to include
fresh–frozen plasma, platelets, red blood cells and
whole blood as essential medicines.11 As an essential
medicine, the agency may then need to charge user
fees or hospitals and allow users or hospitals to
purchase blood from the agency directly. However, a
massive advocacy campaign within the country
might be integral in changing
the pro-public
ideologies of not only the political system, but also
the health facilities and citizens towards blood
transfusion services in the country.
We further suggest that, in building a case for policy
change to allow charging for blood services, there
are several considerations. First, in view of Gerald
and colleagues10 and the current funding trends at
NBTS, the user fee should be portrayed as the cost
of the whole process making the blood safe or what
we call ‘blood processing fee’ and not the cost of
blood per se. Secondly, if blood processing fee is
considered, it can be charged to patients in private
hospitals whose economic wellbeing is considered
higher than those in public hospitals, possibly at a
price higher than the actual blood processing fee.
However, if safe blood users in public hospitals are to
be charged, it must be at a price that is much lower
than the actual blood processing fee. Thirdly, the
agency needs to institutionalize remedial
mechanisms to prevent problems associated with
charging blood processing fee. Foremost, ensuring
quick access of safe blood to patients needing
transfusion who have no alternatives in their
treatment. This is because, patients’ blood
transfusion need is prescribed by physicians in
response to acute illness such as severe bleeding and
thus the service is not demanded electively by the
patient.15 Similarly, since blood processing fees may
result in the irrational use of blood because someone
is paying for it, the agency need to incentivize
4

www.gjmedph.com Vol. 5, No. 4 2016

prescribers to not prescribe irrationally. Lastly, since
there is no direct relationship between the patients
in the hospital (whether inpatient or blood
recipients) and NBTS, the revenues from the user
fees are not guaranteed to flow back to the NBTS.
As such, instutionalization of user fees means that
NBTS must rely on an intermediary, the hospital, to
collect the fees related to transfusion services 15 and
channel them back to NBTS. Based on negative
experiences with ‘cost sharing’ collections and
channeling in other services, it is not guaranteed that
the hospitals would channel the whole proportion of
the collected amount. Therefore, the agency needs
to establish effective financial channeling
mechanisms from hospitals.
The second cost recovery mechanism is by
influencing introducing ‘blood services’ within the
current insurance schemes. Hensher & Jefferys 15
report that 43-percent of surveyed sub Saharan
countries substantially funds blood transfusion (BTS)
services via patient’s charges largely originating
from health insurance funds. In Tanzania, for
example, NBTS data suggest that the insurance
agencies such as; Community Health Funds (CHF),
National Health Insurance Funds and other private
insurance agencies have about 12.2-percent of blood
users, forming a basis for cost-recovery.6,9 However,
the majority of blood users are under-five children
(50-percent) and women with pregnancy related
complications (30-percent), making a total of 80percent of the users 6,8,9 who are mostly uninsured
and are exempted from medical charges. Thus,
relying on insurance may only result into recovering
a small percent of the cost of producing safe blood.
However, compared to other approaches discussed,
the insurance may be an easier and implementable
cost-recovery mechanism which requires minimal
policy changes.
Cost recovery through insurance is part of the
corporate social responsibility (CSR) in which the
company embraces the actions to positively impact
the
environment,
consumers,
employees,
communities, stakeholders and all other members of
the public sphere. Although pregnant women, may
be directly impacted by actions of different
companies, the majority of blood users (under-five
ISSN#- 2277-9604
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children) are often not directly impacted by
companies. Furthermore, the majority of the most at
risk individuals that may require urgent blood
transfusion for example in Road Traffic Accidents
e.g. motorcycle or motor vehicle drivers 16 are
uninsured. Therefore, NBTS must build a strong case
for companies to ensure they understand the link
between their business agendas and safe blood
beneficiaries. This can be achieved by firstly,
increasing awareness of the need for safe blood
among insurance members and how safe blood

contributes to a reduction in deaths compared to
non-transfusion; as well as how it contributes to a
reduction in transfusion related diseases and its cost
effectiveness. Secondly, insisting on the idea of ‘give
and take’ in which the agency clearly elaborates how
the insurance companies may in turn benefit under
CSR, endeavouring a ‘win-win’ situation. In view of
this, we are suggesting
simple mathematical
equations that may be used to establish the cost
effectiveness of blood transfusion services:

Table 2 Mathematical Equations used to Establish the Cost Effectiveness of Blood Transfusion Services
# of lives saved by blood
= [# of patients in need of blood transfusion MINUS (# of patients dying after
transfusion (number of deaths
transfusion PLUS # of patients who needs but dying without receiving
prevented)
transfusion)]
The proportion of HIV infection
prevented through blood screening
(HIV Infections if blood was
transfused without screening)

= [# of HIV positive blood samples detected through screening
# of blood samples collected (donated)

These indicators may be compared across time trajectory (month or years)
The second indicator can be used also for syphilis, Hepatitis B and C.

Thirdly, establishing friendly mechanisms for cost
recovery through insurance, for example, a predetermined percentage of the total amount of
insurance claims invoiced by various hospitals in
other country. This may aim to recover the full or
partial amount invested by NBTS in collection,
processing and distribution of safe blood in all

hospitals country wide. To obtain a percentage of
operational cost recovery through insurance, we are
proposing the following formula with the
assumption that the insurance company meets the
cost for all patients who received blood transfusion
regardless of their insurance package through cross
subsidization:

Table 3 Mathematical Equations for Cost Recovery through Insurance
Desired % recovery

=100 X [(Total operational cost of units supplied by NBTS to the hospital)
(Total insurance claims submitted by the hospital)]

Whereby,
Total operational cost
Total insurance claims

= [# of units distributed to the hospital x Unit cost (76.18 USD)]
= The total amount invoiced by the hospital to the insurance agency within a specific
claim period

The advantages of this model of payment are
considered to be;
5
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1.Recovering the amount equivalent to the actual
units of blood supplied to the hospital by NBTS
2.Avoiding a flat rate, which may unreasonably
overburden the hospitals which didn’t receive blood
within the claim period
3.Removing over reliance on intermediary hospital to
collect insurance payments for NBTS as money will
be deposited directly and on time to the NBTS by
insurance companies
1.An incentive for NBTS to collect and distribute
more blood units;
2.Reducing administration cost to NBTS
3.Creating a win-win situation between NBTS and
insurance companies which may use this as an
opportunity to increase enrolments of members
particularly those as risk.
However, there are two considerations for cost
recovery through insurance. Foremost, if the
recovered amount comes from the hospitals’
insurance claim payments, their buy-in and consent
for deductions are necessary. This consent may be
expressed in their contracts with the insurance
companies which shall channel the agreed
deductions to NBTS directly, therefore removing the
need for a hospital as an intermediary. This will then
be left up to the hospitals to figure out how to
recover the percentage deducted, risking the
burdening of the patients if unregulated. The second
consideration is that, if the equivalent percentage
comes directly from the insurance company in terms
of a percentage of their profits generated, likewise,
buy-in from insurance companies is a prerequisite.
In conclusion, there is a huge demand for safe blood
in the country, however, the existing ‘external’
funding-dependent strategy of collecting blood from
voluntary non-remunerated blood donors are
insufficient to meet the need. Therefore, there is a
need to identify alternative ‘internal’ financial
mechanisms to sustain the supply of safe blood in the
country. It is evident that there are several cost
recovery mechanisms that can be applied in Tanzania
context, such as blood processing fee (user fee) and
blood services within insurance schemes. However, in
each case, policy, ethical and moral issues are the
major barriers. As such, we recommend a continued
search for suitable options, however, if the outlined
6
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strategies are considered for implementation, policy
change, structural adjustments, massive community
sensitization and optimum stakeholder engagement
is warranted to maximize their acceptability within
the country.
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